Hypochlorous acid irrigation reduces the rate of infections in patients undergoing implant-based breast reconstruction☆ Authors: Allison Perko, Emily McCoy, Eden Crowsey, David M Straughan Published: 2026 ABSTRACT AbstractBackgroundThe most common form of breast reconstruction is implant-based breast reconstruction (IBBR), accounting for approximately 81% of all such procedures. However, like all surgical procedures, IBBR has potential complications. The most notable of these complications is infection, which can occur in up to 35% of such cases. In an effort to reduce the frequency of infections in these cases, plastic surgeons are constantly evolving their techniques, including the use of various irrigation solutions to decontaminate the breast pocket at the time of surgery. One of the more novel irrigation solutions being utilized is hypochlorous acid (HOCl), a naturally occurring chemical produced by white blood cells. While there have been studies examining the antimicrobial effect of HOCl, few studies to date have addressed if the addition of HOCl irrigation with IBBR can reduce surgical infections.MethodsWe undertook an IRB-approved, retrospective cohort study of adult female patients, aged 18 years and older, who underwent IBBR from 09/01/2021 – 06/30/2024 at our single institution. Descriptive statistics and Fisher’s exact test were conducted on the dataset to derive sample characteristics and compare outcomes.ResultsThe study included 193 breast procedures in total. The group that did not undergo HOCl irrigation during IBBR included 38 breast with a 13% rate of infection. The group that underwent HOCl irrigation during IBBR included 155 breasts with a 3% rate of infection. The rate of infection was significantly decreased in the patients who received HOCl irrigation intra-operatively, p-value 0.026. There was no significant difference in characteristics between the 2 groups.ConclusionOur study supports the addition of HOCl irrigation to decontaminate the breast pocket during IBBR. The rate of post-operative infection rates significantly decreased after hypochlorous acid irrigation was instituted during IBBR.Keywords: Hypochlorous acid, Implant-based breast reconstruction, Post-op infection Introduction Breast cancer remains a significant public health challenge in the United States, affecting approximately 1 in 8 women over their lifetime.1 Surgical intervention via mastectomy is a primary component of curative treatment. While oncologically necessary, the physical and psychological morbidity associated with mastectomy has driven a 4% increase in breast reconstruction procedures from 2022 to 2023, reaching over 157,000 cases in 2023.2 Implant-based breast reconstruction (IBBR) remains the most prevalent technique, utilized in roughly 81% of all reconstructive cases.3 Despite its popularity and documented benefits to patient quality of life, IBBR is frequently complicated by surgical site infections (SSIs), with reported rates as high as 35%.4,5 These infections not only increase patient morbidity and healthcare costs but also jeopardize reconstructive success, often leading to prolonged antibiotic therapy or operative explantation. Intraoperative pocket irrigation has become a standard practice aimed at reducing the bacterial load and biofilm formation.6 Historically, triple antibiotic solutions (TAS)—typically a combination of cefazolin, gentamicin, and bacitracin—have been the mainstay. However, the efficacy of TAS has recently been scrutinized. Recent 2024 meta-analyses indicate that TAS may not significantly reduce infection rates compared to saline and may even be associated with higher infection frequencies than antiseptic alternatives like povidone-iodine.7 Furthermore, the 2020 FDA withdraw of bacitracin formulations due to toxicity risks have necessitated a reevaluation of traditional irrigation protocols.8 Hypochlorous acid (HOCl), a naturally occurring molecule produced by neutrophils during the oxidative burst, has emerged as a promising alternative. As a potent oxidizing agent, HOCl rapidly inactivates pathogens by disrupting microbial cell membranes and inactivating essential enzymes, while remaining minimally cytotoxic to host tissues due to endogenous antioxidant defenses.9 Recent multicenter data highlighted HOCl’s clinical superiority. In a study of 301 breast reconstructions, irrigation with 0.033% HOCl alone was associated with a significantly lower SSI rate of 1.3% compared to double antibiotic solution alone (8.5%, p < 0.0349) and povidone-iodine alone (8.8%, p = 0.0189).9 While HOCl’s efficacy in managing chronic wounds is well-documented,10 clinical evidence specifically linking intraoperative HOCl breast pocket irrigation to reduced infection rates in the acute IBBR setting remains limited. This study aims to address this gap by evaluating the impact of HOCl irrigation on postoperative infection outcomes in a contemporary cohort of IBBR patients. Methods This retrospective observational cohort study was performed at a single academic medical center in Florida. The study examined the relationship between the use of HOCl irrigation during implant-based breast reconstruction and the subsequent development of surgical site infections. All implant-based breast reconstruction cases performed by a single Plastic Surgeon between July 20, 2022 and December 25, 2024 were included. Surgical site infections were defined as superficial cellulitis requiring antibiotics and deep infection requiring surgical breast implant removal. Each surgical case was followed for at least 180 days to document the incidence of infection. Operative technique All mastectomies were performed by 1 of 2 Breast Surgeons followed by reconstruction by a single plastic surgeon. For the majority of cases, a tissue expander was placed at the time of the initial mastectomy followed by exchange for a permanent implant at a second surgery. During tissue expander placement, the tissue expander is rinsed with betadine and double antibiotic solution. An acellular dermal matrix is secured to the anterior surface of the tissue expander with PDS suture. After the mastectomy has been completed, the breast pocket is irrigated with 50 mL of betadine, followed by 100 mL of double antibiotic solution containing Ancef and Gentamycin. In the HOCl cohort, a final irrigation with 50 mL of HOCl is performed, allowing the hypochlorous acid to instill for approximately 60 s. The non-HOCl irrigation cohort did not receive this 3rd irrigation step. The tissue expander is placed into the breast pocket and secured with PDS suture. Two 15 French round drains are placed in the breast pocket. Following placement, the same irrigation steps are completed as above. The breast pocket is closed with Monocryl suture. The patient is discharged home the same day with post-operative prophylactic antibiotics for 2 weeks. Typically, Cefadroxil is prescribed, or alternatively, Clindamycin if the patient has an allergy. The first surgical drain is removed 1 week after surgery, followed by the second surgical drain removed 2 weeks after surgery. During tissue expander exchange for permanent implant, the breast capsule is opened and the tissue expander is removed. The breast pocket is examined. Capsulotomy or tightening of the capsule with PDS suture is performed as needed for cosmesis. The breast pocket is irrigated with 50 mL of betadine, followed by 100 mL of double antibiotic solution containing Ancef and Gentamycin. In the HOCl cohort, a final irrigation with 50 mL of HOCl is performed, allowing the hypochlorous acid to instill for approximately 60 s. The non-HOCl irrigation cohort did not receive this 3rd irrigation step. The implant is inserted into the breast pocket using a no touch technique. The breast capsule is closed using Monocryl suture. No surgical drains are placed during this procedure. The patient is discharged home the same day with post-operative prophylactic antibiotics for 1 week. Statical analysis Sample characteristics included age, body mass index (BMI), radiation therapy, chemotherapy, diabetes status, ASA class, and time from the procedure to the end of the study. Breast Reconstruction Risk Assessment (BRA) scores for each patient were calculated using the BRA score database (brascore.org), which gave expected rates of infections at both 30-day and 1-year intervals. These demographic and clinical characteristics were summarized using descriptive statistics. Continuous variables were evaluated for distributional normality by visual inspection and reported as means with standard deviations. Categorical variables were summarized as frequencies and percentages. Independent sample t-tests were used to compare continuous variables between patients who received hypochlorous acid irrigation and those who did not. Categorical variables were compared using the Chi-square test, or Fisher’s exact test when expected cell counts were <5. To assess the association between hypochlorous acid irrigation and major infection following surgery, Fisher’s exact test was used due to the small number of outcome events and low expected cell counts, which violated assumptions required for chi-square testing. To quantify the magnitude and direction of this association, risk ratios (RRs), absolute risk difference, odds ratios (ORs), and 95% confidence intervals were calculated. All analyses were two-tailed with a significance threshold of α = 0.05. Statistical analyses were conducted using IBM SPSS Statistics (Version 30.0, IBM Corp., Armonk, NY). Results A total of 193 implant-based breast reconstruction procedures were performed in 67 patients between July 2022 and December 2024. Of these, 155 breasts received intraoperative hypochlorous acid irrigation (HOCl cohort), and 38 did not (non-HOCl cohort). Initial tissue expander placement was performed in 27 non-HOCl breasts (71%) and 72 HOCl breasts (47%), whereas permanent implant placement was performed in 11 non-HOCl breasts (29%) and 83 HOCl breasts (53%). Seven patients (13 breasts) crossed over between cohorts, having their first-stage tissue expander placement in the non-HOCl group and subsequent permanent implant exchange in the HOCl group. All patients underwent the same operative technique apart from the inclusion of HOCl irrigation or not as described in the methods. Sample characteristics (Table 1) Table 1Sample Characteristics.Table 1 dummy alt textCohortMeanp-ValueAgeNon-HOCl55.76 yearsHOCl51.75 years0.095BMINon-HOCl27.55 kg/m2HOCl28.66 kg/m20.186Bra Score InfectionNon-HOCl0.0576Rate 30dHOCl0.05830.930Bra Score InfectionNon-HOCl0.0877Rate 1yHOCl0.09000.781Time to Follow UpNon-HOCl32.53 monthsHOCl17.45 months<0.001*Categorical Characteristics:CohortCountPercentagep-ValueRadiationNon-HOCl (n = 38)821%HOCl (n = 155)2717%0.602ChemotherapyNon-HOCl (n = 38)1642%HOCl (n = 155)6441%0.927DiabetesNon-HOCl (n = 38)00%HOCl (n = 155)138%0.076ASA Class (p = 0.534)Non-HOCl (n=38)PercentageHOCl(n=155)Percentage1411%85%22668%11071%3821%3623%400%11%Operation Performed:Non-HOCl (n=38)PercentageHOCl(n=155)PercentageTissue Expander Placement2771%7247%Permanent Implant Placement1129%8353% Sample Characteristics. Baseline demographic and clinical characteristics are presented in Table 1. Patients in the HOCl group were slightly younger on average (mean = 51.8 years) than those in the non-HOCl group (mean = 55.8 years), although this difference did not reach statistical significance (p = 0.095). There were no statically significant differences between the HOCl and non-HOCl groups when assessing known patient risk factors for infection. BMI did not differ significantly between HOCL and non-HOCl groups (27.6 vs 28.7, respectively; p = 0.186). The HOCl group had 17% of patients who underwent radiation therapy while the non-HOCl group had 21% (p = 0.602). Chemotherapy requirements were similar with 41% of patients undergoing chemotherapy in the HOCl group, compared to 42% in the non-HOCl group (p = 0.927). Diabetes was exclusively observed in the HOCl group at 8%, however this difference did not reach statical significance (p = 0.076). ASA class, ranging from 1–4, also showed no difference between groups (p = 0.523). The HOCl group had 11% ASA class 1, 68% ASA class 2, 21% ASA class 3, and 0% ASA class 4. The non-HOCl group had 5% ASA class 1, 71% ASA class 2, 23% ASA class 3, and 1% ASA class 4. All patients were required to undergo a nicotine test prior to surgery; thus, all patients were negative for nicotine. At 30 days, the HOCl group had an expected BRA score rate of infection of 5.8% vs. 5.8% in the non-HOCl group (p = 0.93). Furthermore at 1-year, the expected rate of infection of the HOCl group was 8.8% compared to 9.0% in the non-HOCl group (p = 0.78). Time from the procedure to the end of the study was significantly longer in the non-HOCl compared to the HOCl due to the retrospective nature of this study (mean = 989.6 vs. 530.6 days, p < 0.001). No adverse events were identified with HOCl use. Infection events (Table 2) Table 2Infection Rate (p = 0.026*).Table 2 dummy alt textNo InfectionInfectionPercentage of Total CasesNo HOCl (n=38)33513.16%HOCl (n=155)14963.87%Total18211Explantation RateImplant ExplantationPercentage of InfectionsNo HOCl (n=38)5100%HOCl (n=155)467%Culture ResultsBacteriaIncidencePercentagePseudomonas aeruginosa333.3%Staph species, not aureus111.1%Bacilli species111.1%Mycobacterium fortuitum111.1%No culture obtained333.3% Infection Rate (p = 0.026*). Patients in the HOCl group had a lower rate of postoperative infection with 6 out of 155 breast procedures resulting in an infection (3.87%), while 5 out of 38 breast procedures in the non-HOCl group resulted in an infection (13.16%). This difference in surgical infection rates between the two groups was statistically significant (p = 0.026). Out of those who developed an infection, 4 of the implants in the HOCl group required explantation (67%) while all 5 of the implants in the non-HOCl group required explantation (100%). Cultures were typically obtained in the OR for patients requiring explantation. The most common bacterial culprit for infection was Pseudomonas aeruginosa. Staph species not aureus, Bacilli species, and Mycobacterium fortuitum were also identified on culture from the breast pocket. To quantify the effect size, the risk ratio (RR) for infection in the irrigation group compared to the non-irrigation group was calculated at 0.20 (95% CI: 0.05–0.77), indicating an 80% relative risk reduction in infection rate. The absolute risk difference (RD) was 10.6%, corresponding to approximately 11 fewer infections per 100 patients treated with HOCl irrigation. The odds ratio (OR) for infection was 0.175 (95% CI: 0.045–0.686), consistent with a significantly lower odds of infection in the HOCl irrigation group. Discussion The results of this retrospective cohort study demonstrate that the intraoperative use of hypochlorous acid (HOCl) irrigation significantly reduces the incidence of surgical site infections (SSIs) in patients undergoing implant-based breast reconstruction (IBBR). With IBBR representing approximately 81% of all breast reconstructions in the United States, managing post-operative complications is a critical priority for patient quality of life, healthcare resource allocation, and progression to adjuvant therapies. Our findings revealed a substantial clinical benefit, with the infection rate dropping from 13.16% in the non-HOCl group to 3.87% in the HOCl group, without changing any additional aspects of the operative technique. This represents an 80% relative risk reduction. These results are particularly impactful because breast cancer patients often require adjuvant systemic therapies; a surgical site infection can lead to dangerous delays in chemotherapy or radiation schedules. By successfully decontaminating the breast pocket, HOCl minimizes the risk of these delays and the potential for operative explantation. Although HOCl irrigation was found to decrease post-operative infection rates in a recent multicenter retrospective trial, their study compared the use of HOCl solution alone versus other antiseptic irrigations alone, without combining their effects.9 All of our patients received betadine and double antibiotic solution irrigation regardless of their cohort with the experimental group receiving additional irrigation with HOCl, representing a realistic control cohort who still had a standard antiseptic technique rather than no irrigation at all. While the infection rate prior to the addition of hypochlorous acid, 13.16%, was below the national average, the addition of hypochlorous acid made a statistically significant reduction to 3.87%. This further demonstrates that the addition of HOCl to a standard antiseptic irrigation regimen can further reduce infection rates. Therefore, our study establishes that there may be benefit in combining these irrigants rather than using them in isolation. However, these findings will need to be further elucidated in later studies. In addition to improving clinical outcomes, routine HOCl irrigation offers significant financial value. At our institution, the cost of HOCl solution is approximately $13.41 per bottle, an inexpensive preventative measure compared to the substantial healthcare costs associated with surgical site infections. In our series, 82% of infected patients ultimately required surgical explantation in the operating room. When weighed against the substantial costs of unplanned reoperation, prolonged hospital stays, and outpatient antibiotic regimens, the low per-patient cost of HOCl represents an exceptionally favorable cost-to-benefit profile. While the results of this study are statistically significant, this study has several limitations. As a retrospective cohort study, it is subject to inherent biases, such as incomplete data collection and potential loss to follow-up. We did our best to overcome some of these biases by first assuring that all patients in the database were included in the analysis. Furthermore, all patients had at least 180 days for follow-up in an attempt to include all possible post-op infections, however if they were seen at a different facility, there may have been an infection undocumented. A potential confounding variable in implant-based reconstruction is the management of surgical drains and systemic antibiotic prophylaxis. In our surgical protocol, drain presence and postoperative antibiotic duration were standardized strictly according to the stage of reconstruction: all first-stage tissue expander placements received two closed-suction drains and two weeks of prophylactic oral antibiotics, whereas second-stage permanent implant exchanges involved no drains and one week of antibiotics. Indwelling surgical drains represent a recognized portal for bacterial entry and colonization, this higher baseline risk inherent to the expander stage was counterbalanced by uniform perioperative protocols across both cohorts. While the non-HOCl group contained a higher proportion of first-stage expander procedures (71%vs. 47%), both procedure types followed identical drain management, antibiotic regimens, and dual-agent baseline antiseptic irrigation (betadine and double-antibiotics) regardless of group allocation. Thus, the substantial risk reduction observed in the HOCl cohort can be primarily attributed to the addition of intraoperative HOCl irrigation. An additional limitation is the relatively small sample size for the non-HOCl group (n = 38) compared to the HOCl group (n = 155). This difference arose because the attending surgeon instituted a rapid practice change after noticing multiple infections in the initial non-HOCl group. Due to the staged nature of implant-based breast reconstruction and the chronological adoption of HOCl, a higher proportion of initial tissue expander placements were performed in the non-HOCl cohort compared to permanent implant exchanges. Consequently, seven patients crossed over between cohorts, undergoing initial tissue expander placement prior to HOCl implementation and subsequent permanent implant exchange with HOCl. Within this subset, only one infection occurred, which arose following the initial non-HOCl expander placement, with no subsequent infections noted after the HOCl-irrigated exchange. While these crossover cases reflect the practical reality of transitioning surgical protocols and did not disproportionately affect our overall comparative outcomes, future prospective studies should evaluate staged reconstructions uniformly from initial expander placement through final reconstruction. Nonetheless, the overall sample size and low incidence of implant infection may render our analysis underpowered to detect modest differences between cohorts. Findings with non-significant p-values should be interpreted with caution, as the possibility of a Type II error cannot be excluded. Larger multicenter studies are warranted to validate these findings. Conclusion The significant decrease in infection rates observed in this study has already led to a practice change at our institution, incorporating HOCl irrigation into all IBBR procedures. HOCl represents a promising advancement in the effort to reduce the morbidity that comes from post-operative infections and improve surgical outcomes for breast cancer survivors. Ethical approval This study was approved by the Institutional Review Board (IRB) of Lakeland Regional Health. Due to the retrospective nature of the study, the requirement for informed consent was waived. This retrospective observational cohort study was conducted and reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines. Funding None. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Footnotes This article has been presented at the 2026 Southeast Surgical Congress Annual Meeting in Amelia Island, Florida. References